NextPlat Corp. (NASDAQ: NXPL, NXPLW) announced that its wholly owned pharmacy subsidiary, PharmcoRx, plans to introduce automated prescription dispensing kiosks from VendRx at select customer clinics and health care facilities. The kiosks will allow patients to obtain prescribed medications onsite following appointments and consultation with a PharmcoRx pharmacist, reducing the need for separate pharmacy visits.
Initial installations are planned for the fourth quarter of 2026, with broader deployment expected throughout 2027. The initiative is designed to improve medication access and adherence while expanding PharmcoRx’s prescription services and relationships with health care providers. VendRx reports approximately 80% formulary coverage per deployment and more than 90,000 successful prescription dispenses since inception, with no wrong-medication releases reported through Oct. 19, 2026, according to its internal records.
NextPlat said the kiosks could help address gaps in pharmacy access, particularly in underserved communities, while allowing clinics to offer prescription dispensing without additional staffing or onsite pharmacy construction. The company expects the program to create an additional prescription channel for PharmcoRx and support its expansion through independent clinics and health care providers. For investors, the latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL.
The announcement matters because medication nonadherence remains a costly and persistent challenge in health care, and onsite dispensing could streamline the patient experience by eliminating a separate pharmacy trip. For clinics, the model offers a way to provide prescription dispensing without the overhead of building a pharmacy or hiring additional staff. For patients in underserved areas, where pharmacy deserts are a growing concern, the kiosks may reduce barriers to obtaining prescribed medications promptly after a consultation.
VendRx’s reported metrics—approximately 80% formulary coverage per deployment and more than 90,000 successful prescription dispenses with no wrong-medication releases through Oct. 19, 2026—suggest the technology has been tested at scale, though the data are drawn from internal records and have not been independently verified. If the deployment proceeds as planned, PharmcoRx could gain a differentiated channel for prescription volume and deepen its ties with independent clinics and health care providers.
The broader implications extend to how pharmacy services are delivered. Automated kiosks could complement traditional pharmacies rather than replace them, but they may intensify competition for prescription volume and accelerate interest in technology-enabled dispensing models. For readers tracking health care innovation, the key milestones will be the fourth-quarter 2026 installations and the pace of expansion in 2027. More details are available in the full press release at https://ibn.fm/dIWEa, and the company’s profile can be found at NextPlat (NASDAQ: NXPL, NXPLW).
This development is reported through BioMedWire, a communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and offers editorial syndication to 5,000+ outlets. Additional services include press release enhancement, social media distribution, and corporate communications solutions.
